Haleon plc: Completion of off-market purchase and Total Voting Rights and Capital

21 March 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces that it has completed the off-market purchase of 44,155,844 ordinary shares of £0.01 each, repurchased from Pfizer Inc. for an aggregate purchase price of approximately £170 million. The purchased ordinary shares have been cancelled.

As at 21 March 2025, the total number of ordinary shares issued by Haleon is 9,039,570,075, of which 4,080,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 9,035,489,870 and this figure may be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. 

Amanda Mellor 

Company Secretary 

Enquiries

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

For more information please visit www.haleon.com